ABBV34
AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh · BMFBOVESPA:ABBV34
101.50 BRL−0.3000 −0.29%
AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh (BMFBOVESPA:ABBV34) last traded at 101.50 BRL, down 0.29% on the day. Over the past year the stock is up 32.21%. Its 52-week range is 58.81 to 101.80. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open98.20
Day range97.00 – 101.50
52-week range58.81 – 101.80
Volume1.18 K
Average volume (10 days)557
Market cap (USD)521.11 B
P/E3,383.33
EPS (TTM) (USD)0.005778
Dividend yield1.48%
Beta (1 year)−0.5348
Revenue (TTM) (USD)66.21 B
Employees57.00 K
Performance
+14.04%1 week
+18.69%1 month
+28.40%3 months
+57.29%6 months
+29.13%Year to date
+32.21%1 year
Technical reading
Bullish
Daily summary of what 11 oscillators and 15 moving averages show. See every indicator
Latest headlines
- AbbVie Price Target Raised to $322.00/Share From $288.00 by GuggenheimDow Jones Newswires · 02 Nov 2026
- Guggenheim maintains AbbVie at Buy, raises price target to $322 from $288TradingView · 02 Nov 2026
- Brise Pharmaceuticals Announces Global License Agreement With Abbvie To Advance The Next-Generation Of Migraine TherapiesReuters · 02 Nov 2026
- AbbVie Price Target Raised to $340.00/Share From $300.00 by Wells FargoDow Jones Newswires · 02 Nov 2026
- Wells Fargo maintains AbbVie at Overweight, raises price target to $340 from $300TradingView · 02 Nov 2026
- AbbVie Price Target Raised to $330.00/Share From $280.00 by RBC CapitalDow Jones Newswires · 02 Nov 2026
- RBC Capital maintains AbbVie at Outperform, raises price target to $330 from $280TradingView · 02 Nov 2026
- AbbVie Is Maintained at Buy by Canaccord GenuityDow Jones Newswires · 02 Nov 2026
Market data from TradingView’s public feed, delayed as the exchange requires. SuperCharting is charting software and gives no investment advice.